Taking antidepressants during pregnancy: what the evidence actually says

You're pregnant, or planning to be, and you take an antidepressant. Maybe you've taken it for years and it changed your life. Now you're being told to weigh the risks. Maybe a well-meaning family member has told you to stop it immediately. Maybe your OB said one thing and your psychiatrist said another.

This is one of the most anxiety-producing decisions in all of medicine, and it deserves a clear, honest look at what the science actually shows.

The Most Important Thing to Understand First

Untreated depression during pregnancy is not a neutral baseline. It carries its own serious risks: higher rates of preterm birth, low birth weight, impaired maternal-infant bonding, difficulty with prenatal care, increased risk of postpartum depression, and in severe cases, suicidal ideation.

Approximately 12% of people in the perinatal period meet criteria for major depressive disorder. This is not rare. And the decision is never "medication vs. no risk." It's always "medication risk vs. untreated illness risk."

The American College of Obstetricians and Gynecologists (ACOG) states clearly: patients should continue their antidepressant when, through shared decision-making, the risk of relapse is determined to be greater than the risk of rare neonatal complications. For women with severe or recurrent depression, discontinuation is more likely to lead to relapse. A meta-analysis showed that discontinuation in patients with mild to moderate depression is not significantly associated with relapse, but for those with more severe illness, the risk-benefit balance typically favors continuing treatment.

SSRIs: The Most Studied Medications in Pregnancy

Selective serotonin reuptake inhibitors are among the best-studied class of medications in pregnancy. While randomized safety trials have not been conducted (and ethically cannot be), multiple large observational studies support a generally favorable safety profile.

Not all SSRIs carry the same level of evidence, however.

Sertraline (Zoloft) has the most reassuring safety data in pregnancy. In the largest study of specific antidepressants and birth defects, a JAMA Psychiatry analysis of data from the National Birth Defects Prevention Study, sertraline had fewer elevated associations with specific birth defects compared to other SSRIs. ACOG notes that sertraline and escitalopram are favored first-line SSRIs because of their efficacy and tolerability profiles.

Escitalopram (Lexapro) also has a favorable profile. In the same JAMA Psychiatry study, there were no elevated associations between escitalopram and the examined birth defects.

Fluoxetine (Prozac) has more data suggesting potential concerns. Meta-analyses have found evidence for a small increased risk of major congenital malformations with fluoxetine, and it has been more commonly implicated in neonatal adaptation syndrome. It also has a very long half-life, which means it stays in the baby's system longer after delivery.

Paroxetine (Paxil) carries the most concern among SSRIs. Multiple meta-analyses have found evidence for increased risk of congenital heart defects with first-trimester paroxetine exposure. A meta-review of 51 meta-analyses concluded that the risk of major congenital malformations could be reduced by avoiding paroxetine and fluoxetine. Most guidelines recommend against starting paroxetine in pregnancy, and switching to a safer alternative if pregnancy is planned.

What About the Baby at Birth?

Neonatal adaptation syndrome is a real but self-limited phenomenon. It can include irritability, tremors, restlessness, poor feeding, and disrupted sleep in the newborn, typically appearing within the first few days of life and resolving within 2 weeks. Most studies estimate the incidence at 10 to 30% of exposed newborns.

ACOG specifically recommends against tapering or discontinuing antidepressants in the third trimester to prevent neonatal adaptation syndrome. The evidence shows that dose reduction does not reduce the risk, and it does increase the risk of maternal relapse.

Persistent pulmonary hypertension of the newborn (PPHN) was previously a major concern, but the FDA has updated its guidance and advised clinicians not to alter their practice based on PPHN concerns. A systematic review found a slightly increased risk (number needed to harm of approximately 1,000), and the FDA considers the causal relationship unclear.

What About Long-Term Effects on the Child?

This is the question that causes the most anxiety, and the answer is reassuring. A large study of over 145,000 pregnancies published in JAMA Internal Medicine examined the association between antidepressant use during pregnancy and neurodevelopmental disorders in children. The study found that initially elevated risks seen in unadjusted analyses systematically disappeared when researchers controlled for confounding factors, particularly the underlying maternal depression itself. When comparing children of mothers who took antidepressants to children of mothers who had depression but discontinued their medication, there was no meaningful difference in neurodevelopmental outcomes.

This pattern was consistent across SSRIs, SNRIs, tricyclic antidepressants, and individual drugs including sertraline, fluoxetine, bupropion, citalopram, and escitalopram.

The takeaway: the apparent association between antidepressants and child developmental outcomes appears to be driven by the depression itself, not the medication.

What About Non-SSRI Options?

SNRIs (venlafaxine, duloxetine) have less safety data in pregnancy than SSRIs, but ACOG notes that if a patient is stable on an SNRI or has had therapeutic benefit in the past, the risk-benefit balance likely favors continuing the previously effective medication. Venlafaxine has shown some concerning associations with specific birth defects in one large study, so it is generally not a first choice for initiation during pregnancy.

Bupropion (Wellbutrin) has moderate safety data in pregnancy. One study found an elevated association between bupropion and diaphragmatic hernia, though the absolute risk remains very small. Bupropion is sometimes chosen when SSRI side effects (particularly sexual dysfunction) are a concern, but it is not typically the first-line recommendation for initiation during pregnancy.

Tricyclic antidepressants have a long track record and are generally considered safe in pregnancy, though they carry more side effects for the mother (sedation, constipation, weight gain) and require monitoring.

What About Newer Treatments?

For postpartum depression specifically, zuranolone (Zurzuvae) is the first oral medication FDA-approved specifically for PPD. It works through GABA-A receptor modulation and has shown rapid antidepressant effects (within days) that are sustained after a 14-day course. It represents a fundamentally new approach to treating postpartum depression.

Brexanolone (Zulresso), an IV infusion previously FDA-approved for PPD, has been commercially discontinued as the manufacturer shifted focus to the oral zuranolone formulation.

Practical Guidance

If you are currently stable on an antidepressant and become pregnant, do not stop your medication without talking to your provider. Abrupt discontinuation carries risks of its own, including withdrawal symptoms and depressive relapse.

If you are planning a pregnancy and currently take paroxetine or fluoxetine, discuss switching to sertraline or escitalopram before conception. This is easier and safer to do before pregnancy than during it.

If you are not currently on medication but develop depression during pregnancy, ACOG and other guidelines recommend psychotherapy (particularly CBT or interpersonal therapy) as first-line treatment for mild to moderate depression. For moderate to severe depression, or when psychotherapy alone is insufficient, medication should be considered, with sertraline being the most commonly recommended first choice.

Deliver in a hospital setting if taking an SSRI or SNRI, so the newborn can be monitored for neonatal adaptation syndrome. Supportive measures like skin-to-skin contact and frequent feedings are usually sufficient for symptom management.

The Bottom Line

The decision to take an antidepressant during pregnancy is deeply personal and should be made through shared decision-making with a provider who understands both the risks of medication and the risks of untreated depression.

The evidence is clear on several points: SSRIs as a class have a generally favorable safety profile in pregnancy. Sertraline and escitalopram have the most reassuring data. Paroxetine and fluoxetine carry slightly higher risks and are generally not recommended as first-line choices during pregnancy. Untreated depression carries real risks to both mother and baby. And the long-term developmental data is reassuring: when you account for the depression itself, antidepressant exposure does not appear to independently increase the risk of neurodevelopmental problems in children.

You are not a bad parent for needing medication. You are a responsible one for asking the question.